3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
3
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
9
Leukemia, Myeloid, Acute
7
Lymphoma
5
Leukemia
5
Lymphoma, Non-Hodgkin
4
Leukemia, Biphenotypic, Acute
4
Squamous Cell Carcinoma of Head and Neck
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Stomach Neoplasms
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, B-Cell
2
Hodgkin Disease
2
Carcinoma, Non-Small-Cell Lung
2
Anemia, Refractory, with Excess of Blasts
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
pembrolizumab
7
Ipilimumab
7
Nivolumab
5
Melphalan
5
Dacarbazine
3
tebentafusp
2
sotrastaurin
2
binimetinib
2
Pemetrexed
2
Crizotinib
2
ADI PEG20
2
utomilumab
1
trametinib
1
tocilizumab
1
siremadlin
1
ruxolitinib
1
relatlimab
1
obinutuzumab
1
fludarabine phosphate
1
fludarabine
1
cemiplimab
1
avelumab
1
Watchful Waiting
1
Toll-Like Receptor 1
1
Standard of Care
1
Solutions
1
Rose Bengal
1
Protein Kinase C
1
Polyethylene Glycols
1
Opdualag
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uveal Melanoma
×
fludarabine phosphate
×
Clear all
NCT07627698
2026-06-04
DUET-MEL
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled